Treatment Options for Functional Abdominal Pain

Pediatric Annals

Volumn 33, Issue 2, 2004, Pages 105-112

  Rudolph, Colin D ^a,b   Miranda, Adrian ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

^c CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESIPRAMINE; DICYCLOVERINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NORTRIPTYLINE; PEPPERMINT OIL; PROTON PUMP INHIBITOR; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ACUPUNCTURE; AGITATION; ALLERGIC REACTION; ANXIETY DISORDER; BEHAVIOR THERAPY; CHILD; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DIAGNOSTIC TEST; DIARRHEA; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DOCTOR PATIENT RELATION; DROWSINESS; DRUG MECHANISM; DYSPHAGIA; ESOPHAGUS PAIN; FAMILY; FAMILY THERAPY; FLATULENCE; FUNCTIONAL ABDOMINAL PAIN; FUNCTIONAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPNOSIS; INSOMNIA; INTESTINAL SPASM; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; MASSAGE; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PATIENT COUNSELING; PSYCHOSOCIAL CARE; QT PROLONGATION; RECTAL BURNING; RECTUM DISEASE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SJOEGREN SYNDROME; SLEEP DISORDER; SOCIAL PSYCHOLOGY; TACHYCARDIA; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0742323366     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20040201-09     Document Type: Review

References (31)

1. Hyams JS, Burke G, Davis PM, Rzepski B, Andrulonis PA. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr. 1996;129(2):220-226.
2. Frank L, Kleinman L, Rentz A, et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24(4):675-689.
3. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569-1580.
4. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109(6):1736-1741.
5. Starfield B, Hoekelman RA, McCormick M, et al. Who provides health care to children and adolescents in the United States? Pediatrics. 1984;74(6):991-997.
6. Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology. 2000;119(5):1276-1285.
7. Van Ginkel R, Voskuijl WP, Benninga MA, Taminiau JA, Boeckxstaens GE. Alterations in rectal sensitivity and motility in childhood irritable bowel syndrome. Gastroenterology. 2001;120(1):31-38.
8. Drossman DA, Sandler RS, McKee DC, Lovitz AJ. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982;83(3):529-534.
9. Hyman PE, Rasquin-Weber A, Fleisher DR, et al: ROME II: Childhood functional gastrointestinal disorders. In: Drossman DA, ed. The Functional Gastrointestinal Disorders, ed 2. Lawrence, Kan.: Allen Press; 2000:533-575.
10. Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med. 1995;123(9):688-697.
11. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med. 1995;122(2):107-112.
12. Drossman DA, Creed FH, Olden KW, et al. Psychosocial aspects of the functional gastrointestinal disorders. In: Drossman DA, ed. Rome II. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment. 2nd ed. McLean, Virginia: Degnon and Associates; 2000:157.
13. Sanders MR, Rebgetz M, Morrison M, et al. Cognitive-behavioral treatment of recurrent nonspecific abdominal pain in children: an analysis of generalization, maintenance, and side effects. J Consult Clin Psychol. 1989;57(2):294-300.
14. Sanders MR, Shepherd RW, Cleghorn G, Woolford H. The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care. J Consult Clin Psychol. 1994;62(2):306-314.
15. Field T, Hernandez-Reif M, Seligman S, et al. Juvenile rheumatoid arthritis: benefits from massage therapy. J Pediatr Psychol. 1997;22(5):607-617.
16. Pintov S, Lahat E, Alstein M, Vogel Z, Barg J. Acupuncture and the opioid system: implications in management of migraine. Pediatr Neurol. 1997;17(2):129-133.
17. Lebenthal E, Rossi TM, Nord KS, Branski D. Recurrent abdominal pain and lactose absorption in children. Pediatrics. 1981;67(6):828-832.
18. Feldman W, McGrath P, Hodgson C, Ritter H, Shipman RT. The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent, abdominal pain. Results in a prospective, double-blind, randomized, controlled trial. Am J Dis Child. 1985;139(12):1216-1218.
19. Peck C, Coleman G. Implications of placebo theory for clinical research and practice in pain management. Theor Med. 1991;12(3):247-270.
20. Weydert JA, Ball TM, Davis MF. Systematic review of treatments for recurrent abdominal pain. Pediatrics. 2003;111(1):e1-11.
21. See MC, Birnbaum AH, Schechter CB, Goldenberg MM, Benkov KJ. Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. Dig Dis Sci. 2001;46(5):985-992.
22. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138(1):125-128.
23. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108(1):65-72.
24. Jarrett M, Heitkemper M, Cain KC, Burr RL, Hertig V. Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome. Dig Dis Sci. 2000;45(5):952-959.
25. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther. 2001 Mar;15(3):277-289.
26. Rivkin A. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin Ther. 2003;25(7):1952-1974.
27. Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother. 2003;4(11):2089-2098.
28. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13(9):1149-1159.
29. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355(9209):1035-1040.
30. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161(14):1733-1740.
31. Lembo T, Wright RA, Bagby B, et al.; Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96(9):2662-2670.